公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
公司地址 100 Summer Street, Suite 2300, Boston, MA, USA, 02110
電話號碼 +1 617 621-7722
傳真號碼 +1 617 494-0480
公司網頁 https://www.ironwoodpharma.com
員工數量 253
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Tammi L. Gaskins Senior Vice President and Chief Commercial Officer -- 28/04/2025
Mr. Thomas A. McCourt Director, President and Chief Executive Officer 美元 867.57K 26/02/2026
Mr. Gregory S. Martini Senior Vice President and Chief Financial Officer -- 26/02/2026
Dr. Michael Shetzline, M.D.,PhD Senior Vice President, Chief Medical Officer and Head of Research and Drug Development 美元 557.57K 28/04/2025
Mr. John Minardo Senior Vice President, Chief Legal Officer and Secretary 美元 531.75K 28/04/2025
Mr. Ronald Silver, C.P.A. Principal Accounting Officer, Senior Vice President and Corporate Controller -- 26/02/2026
 
董事會成員
董事會 職務 更新日期
Dr. Alexander J. Denner, PhD Independent Director 26/02/2026
Mr. Jay P. Shepard Independent Director 26/02/2026
Dr. Mark G. Currie,PhD Independent Director 26/02/2026
Mr. Thomas A. McCourt Director, President and Chief Executive Officer 26/02/2026
Ms. Julie H. McHugh Chairman of the Board 26/02/2026
Ms. Catherine Moukheibir Independent Director 26/02/2026
Mr. Jon R. Duane Independent Director 26/02/2026
Ms. Marla L. Kessler Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:28)
代號 名稱 佔比% 持有日期
FNDASchwab Fundamental U.S. Small CompanyETF1.91%28/02/2026
IWOiShares Russell 2000 Growth ETF0.75%28/02/2026
IBBiShares Biotechnology ETF0.72%28/02/2026
XBIState Street® SPDR® S&P® Biotech ETF0.66%27/02/2026
VTWOVanguard Russell 2000 ETF0.47%31/01/2026
SCHASchwab US Small-Cap ETF™0.43%28/02/2026
FESMFidelity Enhanced Small Cap ETF0.36%27/02/2026
VFVAVanguard US Value Factor ETF0.31%31/12/2025
VHTVanguard Health Care ETF0.27%31/01/2026
FSMDFidelity Small-Mid Multifactor ETF0.27%27/02/2026
PRFZInvesco RAFI US 1500 Small-Mid ETF0.20%27/02/2026
SLYSPDR® S&P 600 Small Cap ETF0.16%31/05/2023
ITOTiShares Core S&P Total US Stock Mkt ETF0.12%28/02/2026
DFASDimensional US Small Cap ETF0.10%27/02/2026
FSMLFranklin Small Cap Enhanced ETF0.09%28/02/2026
SEISSEI Select Small Cap ETF0.09%27/02/2026
SMLVState Street® SPDR® USSmCapLowVolIndETF0.09%27/02/2026
VTWGVanguard Russell 2000 Growth ETF0.08%31/01/2026
EESWisdomTree US SmallCap Earnings ETF0.05%27/02/2026
SCHBSchwab US Broad Market ETF™0.05%28/02/2026
 1    2    3    4  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.